Ernexa Therapeutics posts on-demand video webcast of investor presentation
ERNA•Platform and development details
Materials discuss ERNA-101’s off-the-shelf iMSC platform, preclinical ovarian cancer data, manufacturing, regulatory, and clinical execution.
On-demand investor presentation posted
Ernexa Therapeutics published an on-demand video webcast presentation from a Virtual Investor “Why Now” conference.
Clinical-stage plans and ERNA-101 update
The presentation outlines a planned shift to a clinical-stage profile, with ERNA-101 moving toward an IND filing.
The webcast also highlights plans to start a first-in-human Phase 1 study for ERNA-101.
